...
首页> 外文期刊>Cell death & disease. >A novel long non-coding RNA-PRLB acts as a tumor promoter through regulating miR-4766-5p/SIRT1 axis in breast cancer
【24h】

A novel long non-coding RNA-PRLB acts as a tumor promoter through regulating miR-4766-5p/SIRT1 axis in breast cancer

机译:一种新的长期非编码RNA-PRLB通过调节乳腺癌中的miR-4766-5p / sirt1轴来充当肿瘤启动子

获取原文
           

摘要

Accumulating evidence indicates that long non-coding RNAs (lncRNAs) play a critical role in cancerous processes as either oncogenes or tumor suppressor genes. Here, we demonstrated that lncRNA-PRLB (progression-associated lncRNA in breast cancer) was upregulated in human breast cancer tissues and breast cancer cell lines. Further evaluation verified that lncRNA-PRLB was positively correlated with the extent of metastasis, and its expression was correlated with shorter survival time of breast cancer patients. We identified microRNA miR-4766-5p as an inhibitory target of lncRNA-PRLB. Both lncRNA-PRLB overexpression and miR-4766-5p knockdown could remarkably enhance cell growth, metastasis, and chemoresistance. We also determined that sirtuin 1 (SIRT1) was an inhibitory target of miR-4766-5p, and that SIRT1 was inhibited by both lncRNA-PRLB knockdown and miR-4766-5p overexpression. Significantly, we found that the promotion of cell proliferation and metastasis, the acquisition of chemoresistance, and the increased expression of SIRT1 induced by lncRNA-PRLB overexpression could be partly abrogated by ectopic expression of miR-4766-5p. Taken together, our findings indicated that lncRNA could regulate the progression and chemoresistance of breast cancer via modulating the expression levels of miR-4766-5p and SIRT1, which may have a pivotal role in breast cancer treatment and prognosis prediction.
机译:累积证据表明,长期非编码RNA(LNCRNA)在癌肠或肿瘤抑制基因中发挥着关键作用。在这里,我们证明了LNCRNA-PRLB(乳腺癌中的进展相关的LNCRNA)在人乳腺癌组织和乳腺癌细胞系中上调。进一步的评价核实,LNCRNA-PRLB与转移程度呈正相关,其表达与乳腺癌患者的较短生存时间相关。我们将MicroRNA miR-4766-5P鉴定为LNCRNA-PRLB的抑制靶标。 LNCRNA-PRLB过表达和MIR-4766-5P敲低的敲低可能显着增强细胞生长,转移和化学抑制。我们还确定Sirtuin 1(SIRT1)是miR-4766-5p的抑制靶标,并且通过LNCRNA-PRLB敲低和MIR-4766-5P过表达抑制SIRT1。值得注意的是,我们发现,通过MiR-4766-5P的异位表达,可以将促进细胞增殖和转移,采集化学抑制和由LNCRNA-PRLB过表达诱导的SIRT1的增加的表达。我们的研究结果表明,LNCRNA可以通过调节miR-4766-5p和sirt1的表达水平来调节乳腺癌的进展和化学抑制,这可能在乳腺癌治疗和预后预测中具有关键作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号